Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861083 | 0.91 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL17236065 | 0.84 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22144571 | 0.83 | TDP1 (0.38) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21415441 | 0.83 | TDP1 (0.38) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL12775801 | 0.83 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL23905247 | 0.83 | TDP1 (0.47) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL2623719 | 0.83 | TDP1 (0.40) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21065336 | 0.82 | TDP1 (0.52) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL4573154 | 0.81 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL15061751 | 0.81 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3828275-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3137091-B1 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3690049-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3633039-A1 | COMPOSITIONS AND METHODS | Ionis Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3608406-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3546579-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2016041472-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | 深圳微芯生物科技有限责任公司 | 2016-03-24 | — | — | WO | disclosed |
| WO-2015168635-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168618-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | TDP1 3618/4885MAOA 1182/4885MAOB 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.